<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004051</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-ViTAA-001</org_study_id>
    <nct_id>NCT05004051</nct_id>
  </id_info>
  <brief_title>ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for Abdominal Aortic Aneurysm</brief_title>
  <official_title>Prospective Registry Study to Collect Imaging and Clinical Data Both on Patients With Aortic Aneurysm Disease Undergoing Serial Monitoring, and on Patients Pre and Post Endovascular Repair, Using ViTAA (The Sponsor) Aortic Mapping Technology.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViTAA Medical Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViTAA Medical Solutions</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Prospective Registry study to collect imaging and clinical data both on patients&#xD;
      with aortic aneurysm disease undergoing serial monitoring and on patients pre and&#xD;
      post-endovascular repair, using ViTAA (The Sponsor) aortic mapping technology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a prospective, multi-center, registry of patients that are being assessed with the ViTAA&#xD;
      software. Patients will be enrolled at selected North American centers in the US and Canada.&#xD;
      The Registry will enroll patients from the following two populations:&#xD;
&#xD;
        -  patients who are scheduled and ultimately receive endovascular infrarenal aortic&#xD;
           aneurysm repair (EVAR);&#xD;
&#xD;
        -  patients who do not yet qualify for infrarenal aortic aneurysm repair based on anatomic&#xD;
           size criteria who are enrolled in a serial monitoring program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Composite of aneurysm rupture or critical growth.</measure>
    <time_frame>6 months</time_frame>
    <description>Critical growth defined as an increase of &gt; 0.5 cm in any of the three growth measurements below&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in aortic diameter.&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in ILT.&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in aneurysm sac volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of aneurysm rupture or critical growth.</measure>
    <time_frame>1 year</time_frame>
    <description>Critical growth defined as an increase of &gt; 0.5 cm in any of the three growth measurements below&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in aortic diameter.&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in ILT.&#xD;
Critical growth defined as an increase of &gt; 0.5 cm in aneurysm sac volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CHUM Ancillary Ultrasound Study</measure>
    <time_frame>6 months</time_frame>
    <description>For patients recruited at the CHUM:&#xD;
Correlation between ultrasound and multiphase CT based strain and RAW values&#xD;
Correlation between AAA growth and ultrasound-based strain and RAW maps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CHUM Ancillary Ultrasound Study</measure>
    <time_frame>1 year</time_frame>
    <description>For patients recruited at the CHUM:&#xD;
Correlation between ultrasound and multiphase CT based strain and RAW values&#xD;
Correlation between AAA growth and ultrasound-based strain and RAW maps</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>Patients who are booked for and then subsequently have undergone endovascular repair.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with infrarenal AA without indications for repair undergoing serial monitoring</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ViTAA Analysis</intervention_name>
    <description>Imaging Analysis Software</description>
    <arm_group_label>Patients who are booked for and then subsequently have undergone endovascular repair.</arm_group_label>
    <arm_group_label>Patients with infrarenal AA without indications for repair undergoing serial monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients who are booked for and then subsequently have undergone endovascular repair.&#xD;
&#xD;
          2. Patients with infrarenal aortic aneurysms without indications for repair undergoing&#xD;
             serial monitoring.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is aged 18 years or over&#xD;
&#xD;
          2. Infrarenal Aortic Aneurysm ≥ 45 mm in diameter.&#xD;
&#xD;
          3. Patient meets on-IFU criteria for endovascular reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has a known or clinically suspected major connective tissue disorder,&#xD;
             autoimmune disorder, vasculitis, or aortic dissection.&#xD;
&#xD;
          2. Patient has renal failure (defined as dialysis dependent or serum creatinine ≥2.0mg/dL&#xD;
             or 175umol/L&#xD;
&#xD;
          3. Patients with previous aortic reconstruction in the involved segment.&#xD;
&#xD;
          4. Patients receiving oral or parenteral corticosteroid therapy for other unrelated&#xD;
             disease. (Excludes inhaled corticosteroids).&#xD;
&#xD;
          5. Patient has a sensitivity to contrast imaging agents.&#xD;
&#xD;
          6. Patient has aortic dissection.&#xD;
&#xD;
          7. Patient has atrial fibrillation.&#xD;
&#xD;
          8. Patient has arrhythmia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis Bilodeau</last_name>
    <phone>5145728673</phone>
    <email>denisbilodeau@vitaamedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB - University of Alabama in Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebecca St John</last_name>
      <email>rstjohn@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Beck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGH - Massachusetts General Hospital Fireman Vascular Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tara Bresnahan</last_name>
      <email>tbresnahan2@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Matt Eagleton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC - University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rebekah Roten</last_name>
      <email>rebekah_roten@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCGY - University of Calgary, Peter Lougheed Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Chrsti Findlay</last_name>
      <email>Christi.Findlay@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Paul Petrasek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HSC - Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>April Boyd, MD</last_name>
      <email>aboyd2@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>April Boyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHN - University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Naomi Eisenberg</last_name>
      <email>Naomi.Eisenberg@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Thomas Forbes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Satterthwaite</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>23483</phone_ext>
      <email>jennifer.satterthwaite.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Gilles Soulez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC - McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Amélie Lukaszewski</last_name>
      <phone>+1 514-934-1934</phone>
      <phone_ext>35113</phone_ext>
      <email>marie-amelie.lukaszewski@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Kent MacKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ViTAA Medical Solutions</investigator_affiliation>
    <investigator_full_name>Dr Mark Farber</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

